Peroxisome proliferator-activated receptor translational research and clinical experience

American Journal of Clinical Nutrition

Volumn 91, Issue 1, 2010, Pages

  Cheatham, Wayman Wendell ^a  

^a Bureau of Medicine and Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; CIGLITAZONE; CLOFIBRATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FARAGLITAZAR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLYCOSIDASE INHIBITOR; IMIGLITAZAR; INSULIN; MEGLITINIDE; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAGALITAZAR; ROSIGLITAZONE; SULFONYLUREA; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; EDEMA; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN DEFICIENCY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FAILURE; LIVER TOXICITY; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK; UROGENITAL TRACT TUMOR; WEIGHT GAIN; ADIPOSE TISSUE; ANIMAL; ATHEROSCLEROSIS; BINDING SITE; DRUG EFFECT; INFLAMMATION; LIVER; METABOLISM; METHODOLOGY; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECRETION; SKELETAL MUSCLE; TRANSLATIONAL RESEARCH;

ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; BINDING SITES; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MUSCLE, SKELETAL; OVERWEIGHT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR GAMMA; THIAZOLIDINEDIONES; TRANSLATIONAL RESEARCH;

EID: 74049087919     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2009.28449D     Document Type: Conference Paper

References (51)

1. Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 1988;36:314-39.
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARg). J Biol Chem 1995;270:30221-9.
3. Dieken ML, Federwisch M, De Meyts P. Relationships between the structure of insulin and its physiological effects. In: Federwisch M, Dieken M, DeMeyts P, eds. Insulin and related proteins: structure to function and pharmacology. Dordrecht, Netherlands: Springer, 2004:121-30.
4. Flakoll PJ, Jensen MD, Cherrington AD. Physiologic action of insulin. In: LeRoith D, Olefsky J, Taylor S, eds. Diabetes mellitus, a fundamental clinical text. Philadelphia, PA: Lippincott, Williams and Wilkins, 2004:65-182.
5. Lebovitz H. Insulin secretagogues: old and new. Diabetes Res 1999;7:139-53.
6. Kahn S. The importance of beta cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-58.
7. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
8. Porte D Jr, Kahn SE. Beta cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001;50:S160-3.
9. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992;15:815-9.
10. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30.
11. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:87-97.
12. Hull RL, Kahn SE. Islet amyloid in type 2 diabetes. In: LeRoith D, Olefsky J, Taylor S, eds. Diabetes mellitus, a fundamental clinical text. Philadelphia, PA: Lippincott, Williams and Wilkins, 2004:151-64.
13. LeRoith D. Beta-cell dysfunction and insulin resistance in type-2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002;113 (suppl 6A):S3-11.
14. Caro JF. Clinical review 26: insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991;73:691-5.
15. Kelmendi M, Ylli A, Husi G. Insulin resistance among non-diabetic subjects with normal weight, overweight and obesity, Third World Congress on Insulin Resistance Syndrome. San Francisco, CA, November 2005. Tarzana, CA: Metabolic Endocrine Educational Foundation.
16. Reaven GM. Resistance to insulin-stimulated glucose uptake and hyperinsulinemia: role in non-insulin dependent diabetes mellitus, high blood pressure, dyslipedemia and coronary heart disease. Diabetes Metab 1991;17:78-86.
17. Yu Y, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin resistant adipose tissue. Circ Res 2005;96:1042-52.
18. Gutierrez DA, Puglisi MJ, Hasty AH. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep 2009;9:26-32.
19. Higuchi A, Ohashi K, Kihara S, Walsh K, Ouchi N. Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-a expression. Circ Res 2009;104:1058-65.
20. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.
21. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA 2007;298:194-206.
22. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9.
23. Barnett D, Craig JG, Robinson DS, Rogers MP. Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol 1977;4:455-8.
24. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-41.
25. Maroo A, Tang WHW. Effects of thiazolidinediones on serum lipoproteins. In: Davidson M, Toth P, Maki K, eds. Therapeutic lipidology. Totowa, NJ: Humana Press, 2008:149-58.
26. Flakoll PJ, Jensen MD, Cherrington AD. Physiologic action of insulin. In: LeRoith D, Olefsky J, Taylor S, eds. Diabetes mellitus: a fundamental clinical text. Philadelphia, PA: Lippincott,Williams and Wilkins, 2004:165-82.
27. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35.
28. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 1983;32:830-8.
29. Aleo MD, Doshna CM, Navetta KA. Ciglitazone-induced lenticular opacities in rats: in vivo and whole lens explant culture evaluation. J Pharmacol Exp Ther 2004;312:1027-33.
30. Gale E. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5.
31. Chang AY, Wyse BM, Gilchrist BJ. Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. Diabetes 1983;32:839-45.
32. Graham DJ. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306.
33. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8.
34. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81.
35. Nesto R, Cannon CP, Gerstein HC, et al. Results of the APPROACH trial: assessment on the prevention of progression by rosiglitaxone on atherosclerosis in type 2 diabetes patients with cardiovascular history. Circulation 2008;118:2313 (abstr).
36. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
37. Rosenstock J. for the pioglitazone HCL study group. Effects of pioglitazone on beta-cell function: HOMA bcf. Diabetologia 2000;43(suppl 1):A192 (abstr).
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
39. Matthews D. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 1999;42 (suppl 1):A858 (abstr).
40. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
41. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
42. The Dream (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
43. Finegood DT, McArthur MD, Kojwang D, et al. β-Cell mass dynamics in Zucker diabetic fatty rats. Diabetes 2001;50:1021-9.
44. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM: PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80.
45. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
46. Rubenstrunk A, Hanf R, Hum DW, Fruchart J, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochem Biophys Acta 2007;1771:1065-81.
47. Loke YK, Singh S, Furberg CD. Long term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9.
48. Blackburn GL. From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor γ modulators. Am J Clin Nutr 2010;91 (suppl):251S-3S.
49. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010;91(suppl):254S-7S.
50. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91(suppl):258S-61S.
51. Higgins LS, DePaoli AM. Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation. Am J Clin Nutr 2010;91(suppl):267S-72S.